Navigation Links
Pre-clinical Data Show OrbusNeich's Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
Date:9/23/2009

Stephen M. Rowland, Ph.D., OrbusNeich's vice president of research and development, said, "Combo will enable us to expand on the benefits offered by our Genous technology. The results of this dual coating technology represent the culmination of our engineering efforts to achieve a partitioned effect on the body's response to stent injury. Our collaborative efforts with world class experts have paved the way for our soon to be initiated human clinical trial."

About Genous

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

OrbusNeich's Genous Bio-engineered R stent has been commercially available in over 60 countries since 2005. The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent, Scoreflex(TM), SafeCut(TM), Sapphire(TM), Sapphire NC, Avita(TM), Avita HP and Lumina(TM). OrbusNeich is headquartered in Hong Kong a
'/>"/>

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
2. SuperGens PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia
3. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
4. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
7. Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)
8. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Ezetimibe and Ezetimibe/Simvastatin Combo Pose No Increased Cancer Risk, Study Shows
11. Data Suggests New Antigen-Antibody Combo Test Useful for High Volume Public Health Screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Lannett Company, Inc. (NYSE: LCI ) today ... Genuity 35th Annual Growth Conference on Wednesday, August 12, ... Hotel.  A webcast of the presentation ... encouraged to visit the web site at least 10 ... register, download and install any necessary software.  The presentation ...
(Date:7/30/2015)... 30, 2015  Cleave Biosciences today announced that ... granted the company a key patent providing the ... CB-5083. This newly issued patent, "Fused ... U.S. 9,062,026, allows for claims on the composition ... oral inhibitor of p97, a critical enzyme that ...
(Date:7/30/2015)... , July 30, 2015 Flexpoint Ford, a ... services sectors, today announced that it has entered into ... Bryan Stuart to form Kastle Therapeutics, LLC (Kastle).  ... , will focus on acquiring, developing and commercializing pharmaceuticals ... acquisition opportunities include select therapies already approved for marketing, ...
Breaking Medicine Technology:Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3
(Date:7/30/2015)... , ... July 30, 2015 , ... ... program at ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, telehealth ... 300 cutting-edge health care technology vendors, will take place May 14-17, 2016 in ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At ... and San Bernardino counties, today announced that Dr. Michael Demoratz, PhD, LCSW, CCM ... is a strong proponent of early access to palliative care services for the ...
(Date:7/30/2015)... TX (PRWEB) , ... July 30, 2015 , ... ... Grant Program and fourth annual Institute Scholar Program. In partnership with Patient Experience ... of patient experience, develop leaders on the front lines and throughout the experience ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Mesothelioma ... Lawyer-Spano Mesothelioma Patient Registry Act of 2015’. The bill was introduced in Congress ... King (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The ...
(Date:7/30/2015)... ... July 30, 2015 , ... Boston ... the annual All-Stars Summit. Google Partners is the platform for search marketing agencies ... full support and tools necessary to run successful search marketing campaigns. Google Partners ...
Breaking Medicine News(10 mins):Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2
... ... Times, hundreds of people taking the type-2 diabetes drug Avandia® suffer heart attacks and ... Law firm. , ... (PRWEB) February 26, 2010 -- Maher Law Firm attorneys are investigating possible Avandia® ...
... , ... ... ... ...
... the pain and suffering experienced by women being treated for ... Buffalo School of Social Work professor. , The randomized trial ... constant pain among 124 women with metastatic breast cancer, according ... Social Work, a faculty member in the Buffalo Center for ...
... Study found they showed lower brain activity when on ... News) -- Reduced brain activity may explain why drivers ... report. , They used functional MRI to monitor brain ... using a driving simulator. When they were learning the ...
... , ... eve of its twelfth anniversary Connecticut Governor M. Jodi Rell honored Mountainside Addiction Treatment ... the state. , ... Canaan, CT (PRWEB) February 26, 2010 -- On the eve of its twelfth ...
... mussels, clams and can cause paralysis, scientists say , ... tide" this spring and summer could threaten the New ... Maine Toxicity project. , An abundant cyst population in ... bloom of the toxic algae Alexandrium fundyense . ...
Cached Medicine News:Health News:Maher Law Firm Warns Avandia Users - NY Times Reports - FDA Recommends Recall of Avandia 2Health News:Maher Law Firm Warns Avandia Users - NY Times Reports - FDA Recommends Recall of Avandia 3Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 2Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 3Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 4Health News:Hypnosis can help control pain among women with metastatic breast cancer, UB Researcher finds 2Health News:Connecticut Governor Jodi Rell Honors Mountainside Addiction Treatment Center for its Twelve Years of Operating in Connecticut 2Health News:Connecticut Governor Jodi Rell Honors Mountainside Addiction Treatment Center for its Twelve Years of Operating in Connecticut 3Health News:Predicted 'Red Tide' Could Make Shellfish a Dangerous Dish 2
... Nephroscope, with a stainless steel shaft, combines ... lumbotome, for precise pre-cutting of scar tissue, ... access. The 13.5 Fr. oval working channel ... and lithotripsy probes, and allows a high ...
... Pro Resectoscope is based on the award ... enables the surgeon to perform TURis - ... working element, HF cable and electrodes, Olympus ... resection in saline, supporting both, standard TUR ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
... a PC-based ECG device that can ... and an innovative software. The system ... recording using a standard 12-lead setup ... The software includes two applications: Rest ...
Medicine Products: